Axsome Entered into a Definitive Agreement to Acquire Sunosi from Jazz for the Treatment of Excessive Daytime Sleepiness
Shots:
- Jazz to receive $53M up front & royalty on Axsome's US net sales of Sunosi in current & future indications while the transaction is expected to close in Q2’22. Axsome will get commercial, development, manufacturing & intellectual property rights globally to Sunosi in all existing territories Ex- Asian markets
- The acquisition will boost Axsome’s transition to a global commercial entity & utilize Axsome’s Digital Centric Commercialization platform of launches of AXS-05 for depression & AXS-07 for migraine. The acquisition strengthens Axsome’s neuroscience portfolio
- Sunosi has been in the US to improve wakefulness in adults with EDS associated with narcolepsy or obstructive sleep apnea
Ref: Globe Newswire | Image: Jazz Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
